Cardiff Oncology, Inc. develops clinical-stage cancer therapies centered on PLK1 inhibition and its lead oral inhibitor onvansertib. Company news commonly covers onvansertib in RAS-mutated metastatic colorectal cancer, including the CRDF-004 Phase 2 program evaluating combinations with standard-of-care regimens such as FOLFIRI/bevacizumab and FOLFOX/bevacizumab.
Updates also include preclinical and investigator-initiated work in other oncology settings, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, HER2-low breast cancer models and chronic myelomonocytic leukemia. Corporate releases also address oncology conference presentations, key opinion leader events, executive appointments, investor conferences and Nasdaq inducement equity grants.
Cardiff Oncology (Nasdaq: CRDF) announced participation in the BTIG Biotechnology Virtual Conference on August 10-11, 2020. CEO Dr. Mark Erlander will discuss the advancements and challenges in KRAS inhibition for solid tumors, highlighting onvansertib, a first-in-class Polo-like Kinase 1 (PLK1) inhibitor. The discussion aims to address the potential of onvansertib in treating KRAS-mutated colorectal cancer, a historically challenging area. Attendees can join the presentation through the conference portal.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology company, announced participation in the William Blair Biotech Focus Conference from August 4-6. CEO Dr. Mark Erlander will conduct a fireside chat on August 6 at 10:00 a.m. PT, discussing their investigational drug onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor, currently in trials for KRAS-mutated colorectal cancer, castration-resistant prostate cancer, and leukemia. The webcast can be accessed via Cardiff's website and will be archived for 90 days.